CRSP News and Press, CRISPR Therapeutics AG From 05/23/24

2024-05-23 08:26:07 ET More on CRISPR Therapeutics CRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference (Transcript) Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg Crispr Therapeutics: Market Misunderstanding Is Your ...

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transforma...

2024-05-22 09:10:00 ET With a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (NASDAQ: CRSP) is making it a good time to be a shareholder. But could this biotech's halcyon days be so good that a $10,0...

2024-05-20 03:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-17 17:05:06 ET Gainers: Stronghold Digital Mining ( SDIG ) +7% . New York Mortgage Trust ( NYMT ) +3% . Outbrain  ( OB ) +3% . Aquestive Therapeutics ( AQST ) +2% . Airship AI Holdings ( AISP ) +2% . Losers: ...

2024-05-15 16:12:07 ET CRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference Call May 15, 2024 12:20 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Geoffrey Meacham - Bank of America Merr...

2024-05-15 11:11:00 ET CRISPR Therapeutics (NASDAQ: CRSP) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 2023, CRISPR's revenue plummeted 99.5% year over year, and the...

2024-05-11 10:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always lo...

2024-05-09 14:10:33 ET More on bluebird bio bluebird bio, Inc. (BLUE) Q4 2023 Earnings Call Transcript bluebird bio Is Priced Below IP Value bluebird bio reports Q1 results bluebird bio Q1 2023 Earnings Preview Seeking Alpha’s Quant Rating on b...

2024-05-09 09:32:14 ET Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Trans...